

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

DESIGN OF NEW MONONUCLEOTIDE PRODRUGS: ARYL (SATE) PHOSPHOTRIESTER DERIVATIVES

S. Peyrottes^a; N. Schlienger^a; T. Beltran^a; I. Lefebvre^a; A. Pompon^a; G. Gosselin^a; A. -M. Aubertin^b; J. -L. Imbach^a; C. Périgaud^a

^a Université Montpellier II, Montpellier, cedex 05, France ^b Université Louis Pasteur, Strasbourg, France

Online publication date: 31 March 2001

To cite this Article Peyrottes, S. , Schlienger, N. , Beltran, T. , Lefebvre, I. , Pompon, A. , Gosselin, G. , Aubertin, A. -M. , Imbach, J. -L. and Périgaud, C.(2001) 'DESIGN OF NEW MONONUCLEOTIDE PRODRUGS: ARYL (SATE) PHOSPHOTRIESTER DERIVATIVES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 315 — 321

To link to this Article: DOI: 10.1081/NCN-100002302

URL: <http://dx.doi.org/10.1081/NCN-100002302>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

DESIGN OF NEW MONONUCLEOTIDE PRODRUGS: ARYL (SATE) PHOSPHOTRIESTER DERIVATIVES

S. Peyrottes,^{1,*} N. Schlienger,¹ T. Beltran,¹ I. Lefebvre,¹
A. Pompon,¹ G. Gosselin,¹ A.-M. Aubertin,² J.-L. Imbach,¹
and C. Périgaud¹

¹UMR 5625 CNRS - UM II, Université Montpellier II, cc 008,
place E. Bataillon, 34095 Montpellier cedex 05, France

²INSERM U 74, Université Louis Pasteur, 3 rue Koeberlé,
67000 Strasbourg, France

ABSTRACT

Synthesis, biological activities and decomposition kinetics of novel phosphotriester derivatives of 3'-azido-2',3'-dideoxythymidine (AZT) bearing a *S*-*t*Butyl-2-thioethyl (*t*BuSATE) group and L-tyrosinyl residues are reported. All the derivatives appeared to be potent inhibitors of HIV-1 replication in various cell culture experiments. The proposed decomposition process of these mixed phosphotriesters may involve successively an esterase and then a phosphodiesterase activation.

The antiviral activity of nucleoside analogues is closely related to their ability to be phosphorylated intracellularly. Many strategies have been envisaged to mask or reduce negative charges of nucleoside 5'-monophosphates, thereby forming more lipophilic derivatives (pronucleotides) which would be expected to revert back to the corresponding 5'-mononucleotides inside cells (1). Research progressed in this way with the design of mononucleoside phosphotriester derivatives incorporating two *S*-acyl-2-thioethyl (SATE) groups as biolabile phosphate protections (2). The decomposition pathway of such pronucleotides involves two successive esterase

*Corresponding author.

activation steps (3). *In vivo* pharmacokinetic studies of bis(*t*BuSATE) phosphotriesters seem to demonstrate that the second enzyme-mediated step could be considered limiting (4,5). Therefore, we decided to explore mixed phosphotriester derivatives bearing only one SATE chain and another moiety susceptible to be hydrolyzed selectively by an enzymatic system other than esterases. We previously showed that the mononucleoside phenyl (*t*BuSATE) phosphotriester derivative of AZT **1** (Fig.) leads *in vitro* to the selective intracellular release of the corresponding 5'-mononucleotide (6). Herein, we would like to report the synthesis and the evaluation of new phosphotriesters **2–4** bearing L-tyrosinyl residue as aryl substituent (Fig.).





Figure 1. Structure of the studied arylphosphotriester derivatives of AZT.

Synthesis. The targeted compounds were obtained via a phosphoramidite approach (Scheme 1).

The phosphitylating agent **5** bearing the SATE moiety and the desired tyrosinyl residue was obtained from commercially available bis(diisopropylamino) chlorophosphine with subsequent coupling of the SATE chain (**7**) and then the aryl precursor **6** in presence of 1*H*-tetrazole. The reaction of the tyrosinyl (*t*BuSATE) phosphoramidite intermediate **5** with AZT, followed by *in situ* oxidation using *tert*-butyl hydroperoxide, afforded the fully protected phosphotriester derivatives **2**. Treatment of compound **2** in various acidic conditions gave rise to partially protected **3** and to the fully deprotected tyrosinyl (*t*BuSATE) phosphotriester derivative of AZT **4**.

Antiviral evaluation. All the derivatives were evaluated for their *in vitro* anti-HIV activity and were potent inhibitors of HIV-1 replication in cell culture experiments (Table 1).

In contrast to AZT, the tyrosinyl (*t*BuSATE) phosphotriesters **2–4** exhibited significant anti-HIV effects in thymidine kinase-deficient cells (CEM/TK[−]) with EC₅₀ values in the same range as the one observed for the pronucleotide **1**. These results suggest that the mixed aryl phosphotriesters **2–4** were able to deliver intracellularly of the 5'-mononucleotide of AZT (AZTMP) and can be considered as new pronucleotides.



Scheme 1. Synthesis of tyrosinyl (tBuSATE) phosphotriester derivatives of AZT Reagents: (i) (CH₃)₂NCH[OCH₂C(CH₃)₃]₂, tBuOH, toluene; (ii) tBuSATEOP[N(iPr)₂]₂, 1H-tetrazole, HN(iPr)₂, CH₃CN; (iii) AZT, 1H-tetrazole, CH₃CN, then tBuOOH, toluene; (iv) 30 % HCl, Et₂O solution; (v) 10 % TFA, CH₂Cl₂, then HCl, dioxane solution.

Stability studies. Using a previously published procedure (3), the decomposition pathways and kinetic data of compounds 2–4 were studied in total CEM-SS extracts in order to mimic the conditions inside the cells. The metabolites formed during the incubation of the phosphotriester were identified by HPLC-MS and by coinjection with authentic samples. For this purpose, the intermediates 8, 10 and 11 (Schemes 2 and 3) were synthesized using a H-phosphonate approach (8).

These results indicate that the decomposition mechanism for the fully protected phosphotriester 2 (Scheme 2) occurred following two concomitant

Table 1. Anti-HIV-1 Activity in Various Cell Lines of Mixed Aryl Phosphotriester Derivatives 2–4 in Comparison to the Parent Nucleoside AZT and to the Phenyl (tBuSATE) Phosphotriester Derivative 1 as Reference Pronucleotide^a

Compound	CEM-SS		MT-4		CEM/TK ⁻	
	EC ₅₀ ^b	CC ₅₀ ^c	EC ₅₀ ^b	CC ₅₀ ^c	EC ₅₀ ^b	CC ₅₀ ^c
AZT	0.003	>1	0.015	>1	>100	>100
1	0.002	>10	0.070	>10	3.5	>10
2	0.034	>1	0.250	>1	0.90	>1
3	0.004	>10	0.042	>10	2.7	>10
4	0.006	>100	0.075	>10	29	>100

^aAll data represent average values for at least three separate experiments. The variation of these results under standard operating procedures is below ± 10 %. ^bEC₅₀: effective concentration (μ M) or concentration required to inhibit the replication of HIV-1 by 50%.


^cCC₅₀: cytotoxic concentration (μ M) or concentration required to reduce the viability of uninfected cells by 50%.

esterase-mediated steps: (i) a main decomposition pathway (65%) resulting to the loss of the *t*Butyl group on the tyrosinyl residue, and leading to the phosphotriester **7**; (ii) hydrolysis of the *t*BuSATE chain giving rise to the formation of the corresponding phosphodiester **8**. The metabolites **7** and **8** were then converted to the aryl phosphodiester **9**, which was further hydrolyzed into AZTMP through phosphodiesterase activity.


The two esterase-mediated steps were also observed for phosphotriester **3** in total CEM-SS cell extracts (Scheme 3). Nevertheless, compared to its analog **2**, the major decomposition pathway (93%) of **3** corresponds to the loss of the *t*BuSATE chain from **4** leading to phosphodiester **10**. This is probably due to the presence of the ionisable (at physiological pH) amino function in the vicinity of the ester functionality. Finally, the metabolite **10** is directly converted into AZTMP (phosphodiesterase activity).

The decomposition pathway of the fully deprotected phosphotriester **4** resulted successively in the removal of the SATE moiety (metabolite **11**, Scheme 3) and then of the tyrosinyl residue.

The half-lives of the mononucleoside phosphotriesters and the resulting metabolites are summarized in Table 2. Comparison of the enzymatic stability of the arylphosphodiester **10** and **11** (Scheme 3) demonstrated that the presence of a *t*Butyl ester functionality on the tyrosinyl residue of the phosphodiester derivatives seems to modify the rate of the phosphodiesterase mediated step (Table 2). In order to



Scheme 2. Proposed decomposition mechanism of the fully protected derivative **2** in total CEM-SS cell extracts.



Scheme 3. Proposed decomposition mechanism of derivatives **3** and **4** in total CEM-SS cell extracts.

confirm that the conversion of the aryl phosphodiester metabolites to AZTMP was not due to a chemical process, the stability of metabolite **11** was determined in phosphate buffer (pH 7) and in denatured cell extract. No degradation of this entity was observed after a week of incubation at 37°C.

The comparison of kinetic data, especially the estimated half-life of AZTMP formation, Log P values (which have been correlated with the passive diffusion of compounds through cellular membranes) and EC₅₀ in CEM-SS/TK⁻ cells for the studied compounds, indicates that the observed antiviral activity is closely related to both parameters (Table 3).

It is known that a time-dependent relationship is required between the release of the phosphorylated forms from the pronucleotide and expression of the cellular target in order to observe an antiviral effect (2,9,10). Thus, derivative **4** presents

Table 2. Calculated Half-Lives of the Phosphotriester Derivatives **2–4** and Their Metabolites in CEM-SS Cell Extracts, and Corresponding Pseudo First-Order Rate Constants

	Compound		Metabolites	
	2	7	8	9
t _{1/2}	<10 min	28 min	40 min	4.3 h
k (min ⁻¹)	0.061	0.025	0.017	0.0027
	3	10	4	11
t _{1/2}	20 min	3.9 h	1.2 h	25 h
k (min ⁻¹)	0.035	0.0030	0.0093	0.00045

Table 3. Estimated Half-Lives of AZTMP Formation, Apparent Water Octanol Partition Coefficient (Log P) and EC₅₀ in CEM/TK[−] Cells

	t _{1/2} of AZTMP Formation	Log P	EC ₅₀ (μM) in CEM/TK [−]
2	5.3 h	4.29	0.9
3	5.1 h	2.90	2.7
4	25 h	0.24	29

the weaker activity whereas fully protected **2** appeared the more potent, due to favorable properties (fast release of AZTMP and high lipophilicity).

CONCLUSION

The present study demonstrates that aryl (*t*BuSATE) phosphotriester derivatives of AZT **2–4** are able to deliver the parent 5'-mononucleotide efficiently and they can be considered as novel pronucleotides. The proposed mechanism of decomposition of these mixed phosphotriesters involves successively an esterase and a phosphodiesterase step. The large number of chemical modifications which could be envisaged on the aryl moiety enables the search for antiviral mononucleotide prodrugs with a balance between aqueous solubility, lipophilicity, and enzymatic stability in order to envisage further *in vivo* pharmacological studies. Work on this area is currently in progress in our group.

ACKNOWLEDGMENTS

These investigations were supported by grants from the Agence Nationale de Recherches sur le SIDA (ANRS) and the Fondation pour la Recherche Médicale (FRM).

REFERENCES

1. Meier, C. *Synlett* **1998**, 233–242.
2. Périgaud, C.; Gosselin, G.; Imbach, J.-L. In *Biomedical Chemistry/Applying Chemical Principles to the Understanding and Treatment of Disease*; Torrence, P. F., Ed.; John Wiley & Sons Inc.: New York, 2000; Vol. 5, pp. 115–141.
3. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kim, A.; Gosselin, G.; Imbach, J.-L. *J. Med. Chem.* **1995**, 38, 3941–3950.
4. Placidi, L.; Périgaud, C.; Cretton-Scott, E.; Gosselin, G.; Pierra, C.; Schinazi, R. F.; Imbach, J.-L.; Sommadossi, J.-P. *Antiviral Res.* **1998**, 37, 87.



ARYL (SATE) PHOSPHOTRIESTER DERIVATIVES

321

5. Martin, L. T.; Cretton-Scott, E.; Placidi, L.; Faraj, A.; Loi, A. G.; Schinazi, R. F.; Mc Clure, H. M.; Gosselin, G.; Imbach, J.-L.; Sommadossi, J.-P. *Nucleosides Nucleotides, Nucleic Acids* **2000**, *19*, 481–499.
6. Schlienger, N.; Peyrottes, S.; Aubertin, A.-M.; Gosselin, G.; Imbach, J.-L.; Périgaud, C. *Nucleosides Nucleotides* **1999**, *18*, 1025–1026.
7. Alvarez, K.; Vasseur, J.-J.; Beltran, T.; Imbach, J.-L. *J. Org. Chem.* **1999**, *64*, 6319–6328.
8. Kuyl-Yeheskiely, E.; Tromp, C. M.; Van der Marel, G. A.; Van Boom, J. H. *Tetrahedron Lett.* **1987**, *28*, 4461–4464.
9. Balzarini, J.; Naesens, L.; Aquaro, S.; Knispel, T.; Perno, C.; De Clercq, E.; Meier, C. *Mol. Pharmacol.* **1999**, *6*, 1354–1361.
10. De Clercq, E. *Int. Antiviral News* **2000**, *8*, 53–56.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002302>